CCPIT Patent and Trademark Law Office has set up a special team focusing on HPV projects, helping clients obtain high-quality patents in this field, maximize the value of their IP assets, and eliminating the infringement risks of new HPV vaccine before going listed.
HPV vaccine turned out to be the best way to prevent occurrence of cervical cancer, the third most common cancer among women aged 15 to 44, but up till now the approved listed HPV vaccines mainly include divalent, quadrivalent and nine-valent cervical cancer vaccines. Applicants seeking to obtain intellectual property protection and patent rights for their newly developed HPV vaccines are under challenge and were given little chance to compete with the existing ones on the market.
The new team provides a complete patent protection solution by studying the patent portfolios of key players on the market and by figuring out the applicants’ key patents thus helping new HPV vaccines to achieve high intellectual property value.
中国贸促会专利商标律师事务所组建HPV项目知产团队
中国贸促会专利商标律师事务所组建了HPV项目知识产权保护团队，帮助客户在此领域获得高质量专利、最大化其知产商业价值，并助力研发的新型HPV疫苗排除侵权风险、成功上市。
在中国，宫颈癌是15岁至44岁女性中第三大高发癌症，接种HPV疫苗预防感染是目前防止宫颈癌的有效手段。截至目前，国内获批上市的HPV疫苗主要包括二价、四价和九价宫颈癌疫苗。研发的新型HPV疫苗作为产品是否具有足够的创新性、是否能够得到专利保护、研发的疫苗一旦上市是否会侵犯他人在先的专利权，这些都是亟待回答的问题。
新组建的团队通过充分检索和分析主要竞争对手的知识产权状况，全面检索和梳理相关技术，围绕疫苗产品提出了整体专利保护解决方案，助力创造疫苗知识产权实现高价值。
To contact the editorial team, please email ALBEditor@thomsonreuters.com.
